Human natural killer cells in major histocompatibility complex class I deficiency.

February 11, 2021 By:
  • Patil ND
  • Theresine M
  • Zimmer J.

We read with interest the personal reflection of. Hans-Gustaf Ljunggren from the Karolinska Institute (KI) about the path towards natural killer (NK) cell-based cancer immunotherapy.(1) The manuscript includes a paragraph about mouse major histocompatibility complex (MHC) class I deficiency, and as we published several papers about the equivalent entity, Human Leukocyte Antigen (HLA) class I defects, we were inspired to briefly remind the NK cell status in these diseases.

2021 Feb. Scand J Immunol.e13029. Online ahead of print.
Other information